Traded Oct 1 · filed 5 days later
Derivative exercise or conversion — not an open-market buy.
Loading…
Planned for Oct 5, 2026 · Notice filed Oct 5, 2026
A Castle Biosciences officer told the SEC about a plan to sell $1.06M of Castle Biosciences shares around Oct 5, 2026. The shares were not acquired as compensation. That is a tiny part of all Castle Biosciences shares.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
None found in footnotes
Only flagged when a footnote says so; never inferred
Traded Oct 1 · filed 5 days later
Derivative exercise or conversion — not an open-market buy.
Kristen M Oelschlager (Chief Operating Officer) sold ~$100K of Castle Biosciences
Scheduled in advanceKristen M Oelschlager (Chief Operating Officer) sold ~$49K of Castle Biosciences
Scheduled in advance